© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
Expert cardiologists provide a brief overview of the standard of care for lipid disorders and focus on a rapidly emerging, newer treatment option for managing dyslipidemia.
March 22nd 2021
Manesh Patel, MD, discusses the pathophysiology of the relationship between hypercholesterolemia and cardiovascular disease.
Expert panel of cardiologists provide their perspective on the specific population that may be at a risk of developing hyperlipidemia.
March 29th 2021
Norman Lepor, MD, FACC, FAHA, FSCAI, shares how he would identify and monitor patient populations at high risk for CV morbidity and mortality.
Linda Hemphill, MD, shares her views on how familial hypercholesterolemia impacts the assessment of high-risk patients.
April 5th 2021
Dean Karalis, MD, provides his perspective on intensive LDL lowering in patients with risk for high cholesterol and related disorders.
Manesh Patel, MD, briefly addresses the mechanism of action of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.
April 12th 2021
Cardiologists briefly review the outcomes data and practical implications of novel treatment options for hyperlipidemia.
Panel of experts discuss the use and safety profile of purified icosapent ethyl compound (EPA) in prevention of CV risk.
April 19th 2021
Experts review in detail the emerging use of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.
Norman Lepor, MD, FACC, FAHA, FSCAI, reviews the efficacy of inclisiran in terms of LDL reduction based on the pooled analysis of the phase 3 ORION trials.